Physician

Laili Soleimani, MD

According to 2025 Medicare claims, Laili Soleimani, MD (NPI: 1336372861) practices general psychiatry in the New York-Jersey City-White Plains, NY-NJ market, with the plurality of this provider's patient population coming from New York, NY. This provider's primary affiliated billing organization is ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (NPI: 1033482518; TIN: 611661781) and primary practice location at 10029-6500. Soleimani is affiliated with the CVS Accountable Care Organization, Inc. (ACO ID: D0061), participating under the REACH model.

Soleimani's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 124 traditional Medicare patients, billed 316 HCPCS/CPT codes, and received $26,879 in Medicare payments. The top billing code was 99205 (New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more). Part D data shows 484 prescription claims across 97 beneficiaries totaling $9,187 in drug costs, led by Mirtazapine (Mirtazapine). Open Payments data shows 1 records totaling $2,793. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a higher plateau to a lower plateau, from $109,491 to $26,879. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $17,975 and ending at $9,187. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	140	1,683	$109,491
2016	86	753	$51,670
2017	96	1,064	$75,993
2018	85	1,146	$79,385
2019	87	1,072	$76,769
2020	80	893	$67,452
2021	75	524	$38,515
2022	65	717	$52,279
2023	112	572	$48,113
2024	124	316	$26,879

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	75	376	$17,975
2016	38	167	$8,864
2017	28	126	$7,140
2018	19	68	$2,495
2019	19	58	$1,891
2020	128	797	$14,100
2021	128	1,152	$23,567
2022	58	198	$8,139
2023	54	161	$5,585
2024	97	484	$9,187

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	42	42	$167
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	50	73	$147
99231	Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes	23	36	$43
G2212	Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or	58	87	$27
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	17	22	$14

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Mirtazapine	Mirtazapine	33	1,890	$1,168
Aripiprazole	Aripiprazole	11	390	$921
Duloxetine Hcl	Duloxetine Hcl	34	1,350	$811
Trazodone Hcl	Trazodone Hcl	27	1,620	$634
Quetiapine Fumarate	Quetiapine Fumarate	72	2,621	$545

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	0	$0	N/R
Research Payments	Reported research-related payment or transfer-of-value amount.	1	$2,793	E.R. Squibb & Sons, L.L.C.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Laili Soleimani, MD?

Tedicare shows public-source Medicare data for Laili Soleimani, MD (NPI 1336372861), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Laili Soleimani, MD have ACO affiliation data?

Laili Soleimani, MD is shown with ACO affiliation data for CVS Accountable Care Organization, Inc. (REACH, ACO ID D0061).

What billing organization is linked to Laili Soleimani, MD?

Laili Soleimani, MD is linked to ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (billing NPI 1033482518) in the available physician profile data.

Does Laili Soleimani, MD have Open Payments data?

Laili Soleimani, MD has 1 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.